Kynos Therapeutics is a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases
Kynos Therapeutics is a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases. Its lead investigational asset is KNS366, a first-in-class inhibitor of the enzyme kynurenine 3-monooxygenase (KMO).